Khanna A, Poduri C D, Murugan P, Kumar S, Sugunan V S, Shenoy K T, Das M R
Rajiv Gandhi Centre for Biotechnology, Jagathy, Trivandrum, Kerala, India.
Acta Virol. 1998 Jun;42(3):141-5.
A peptide-based enzyme immunoassay (PBEIA) has been developed using synthetic peptides whose sequences were selected from the core, envelope and non-structural regions of the prototype hepatitis C virus (HCV) genome. Results of PBEIA of sera obtained from several patients with various liver disorders were compared to those of commercial enzyme-linked immunosorbent assays (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR). A large number of samples, which were repeatedly negative in commercial ELISA, were positive in PBEIA. There was a good correlation between the results of PBEIA and RT-PCR. The developed PBEIA proved to be a sensitive assay that had high specificity and was capable of detecting antibodies in various HCV-related liver disorders including the acute phase of the infection.
一种基于肽的酶免疫测定法（PBEIA）已被开发出来，该方法使用的合成肽序列是从丙型肝炎病毒（HCV）原型基因组的核心区、包膜区和非结构区中选取的。将从患有各种肝脏疾病的几名患者获得的血清进行PBEIA检测的结果，与商业酶联免疫吸附测定法（ELISA）和逆转录-聚合酶链反应（RT-PCR）的结果进行了比较。大量在商业ELISA中反复呈阴性的样本，在PBEIA中呈阳性。PBEIA的结果与RT-PCR的结果之间存在良好的相关性。所开发的PBEIA被证明是一种敏感的检测方法，具有高特异性，能够检测包括感染急性期在内的各种HCV相关肝脏疾病中的抗体。
